Physician profile
Shawn Lee
NPI 1942695374
$16,477.23
in general payments reported to CMS, 2019-2025
25 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.89 · 2020: $244 · 2021: $668 · 2022: $3,806 · 2023: $971 · 2024: $8,497 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,710 · Grant: $2,000 · Travel and Lodging: $1,437 · Entertainment: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,710.04 |
| Grant | $2,000.00 |
| Travel and Lodging | $1,437.26 |
| Entertainment | $228.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,793.13 | 2024-2025 | Aurora Ev-Icd Mri Surescan, Micra, Pulseselect |
| Boston Scientific Corporation | $1,527.43 | 2024-2025 | Watchman Flx, Farapulse, General - Therapies |
| Abbott Laboratories | $1,460.77 | 2024-2025 | Aveir, Mitraclip, Ensite |
| Biotronik INC. | $734.88 | 2024-2025 | Biomonitor, Acticor 7 Vr-T Dx, Selectra |
| Biosense Webster, INC. | $401.05 | 2024-2025 | Carto 3, Nuvision Ice Catheter |
| Cardiva Medical, INC. | $234.15 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Ensoetm, Cardiva Vascade Mvp Vvcs 6-12f |
| Stereotaxis INC | $228.04 | 2024 | Genesis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.82 | 2024-2025 | Jardiance |
| Atricure, INC. | $174.97 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Baxter Healthcare | $163.12 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $64.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $47.82 | 2024 | Verquvo |
| Impulse Dynamics (USA) INC. | $39.88 | 2025 | Optimizer |
| Janssen Pharmaceuticals, INC | $37.48 | 2024 | Xarelto |
| Lilly USA, LLC | $34.86 | 2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $34.25 | 2024 | Andexxa |
| Alnylam Pharmaceuticals INC. | $28.37 | 2024 | Onpattro |
| Inspire Medical Systems, INC. | $24.38 | 2025 | Inspire |
| Amgen INC. | $21.15 | 2024 | Repatha |
| Kiniksa Pharmaceuticals, Ltd. | $21.00 | 2023 | Arcalyst |
| Cvrx, INC. | $20.06 | 2024 | Barostim Neo System |
| Imperative Care, INC | $18.60 | 2025 | Symphony Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.29 | 2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.94 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.